NBTX
Income statement / Annual
Last year (2025), Nanobiotix's total revenue was $29.64 M,
a decrease of 512.28% from the previous year.
In 2025, Nanobiotix's net income was -$23.96 M.
See Nanobiotix,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$29.64 M |
-$7.19 M |
$36.21 M |
$4.78 M |
$2.65 M |
$2.33 M |
$2.54 M |
$3.48 M |
$3.72 M |
$5.42 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$29.64 M
|
-$7.19 M
|
$36.21 M
|
$4.78 M
|
$2.65 M
|
$2.33 M
|
$2.54 M
|
$3.48 M
|
$3.72 M
|
$5.42 M
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$23.12 M
|
$40.54 M
|
$38.40 M
|
$32.64 M
|
$30.38 M
|
$24.33 M
|
$30.41 M
|
$20.89 M
|
$17.73 M
|
$16.92 M
|
| General & Administrative Expenses |
$20.22 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$20.22 M
|
$20.53 M
|
$22.05 M
|
$17.86 M
|
$19.43 M
|
$14.61 M
|
$18.91 M
|
$12.65 M
|
$11.26 M
|
$10.36 M
|
| Other Expenses |
-$2.88 M
|
$134.00 K
|
$2.54 M
|
$985.00 K
|
$5.41 M
|
-$188.00 K
|
$0.00
|
$0.00
|
$1.00 K
|
$0.00
|
| Operating Expenses |
$40.46 M
|
$61.20 M
|
$62.99 M
|
$51.48 M
|
$55.23 M
|
$38.75 M
|
$49.32 M
|
$33.55 M
|
$28.99 M
|
$27.28 M
|
| Cost And Expenses |
$40.46 M
|
$61.20 M
|
$62.99 M
|
$51.48 M
|
$55.23 M
|
$38.75 M
|
$49.32 M
|
$33.55 M
|
$28.99 M
|
$27.28 M
|
| Interest Income |
$985.00 K
|
$2.63 M
|
$1.22 M
|
$256.00 K
|
$0.00
|
$0.00
|
$105.00 K
|
$34.00 K
|
$33.03 K
|
$59.49 K
|
| Interest Expense |
$10.40 M
|
$8.09 M
|
$7.98 M
|
$5.84 M
|
$699.49 K
|
$333.00 K
|
$4.79 M
|
$847.00 K
|
$108.37 K
|
$102.20 K
|
| Depreciation & Amortization |
$1.50 M
|
$592.00 K
|
$551.00 K
|
$1.50 M
|
$1.56 M
|
$1.75 M
|
$1.77 M
|
$619.00 K
|
$454.00 K
|
$482.79 K
|
| EBITDA |
-$12.07 M |
-$67.67 M |
-$23.69 M |
-$44.22 M |
-$45.61 M |
-$34.86 M |
-$45.01 M |
-$29.45 M |
-$24.81 M |
-$21.37 M |
| EBITDA Ratio |
-0.41
|
9.41
|
-0.65
|
-9.26
|
-17.23
|
-14.99
|
-17.71
|
-8.46
|
-6.67
|
-3.94
|
| Operating Income Ratio |
-0.36
|
9.51
|
-0.74
|
-9.78
|
-19.86
|
-15.67
|
-18.41
|
-8.64
|
-6.79
|
-4.03
|
| Total Other Income/Expenses Net |
-$13.14 M
|
$361.00 K
|
-$12.80 M
|
-$10.33 M
|
$5.58 M
|
$2.85 M
|
-$4.13 M
|
-$278.00 K
|
-$876.00 K
|
$64.61 K
|
| Income Before Tax |
-$23.96 M
|
-$68.03 M
|
-$39.58 M
|
-$57.03 M
|
-$47.00 M
|
-$33.58 M
|
-$50.91 M
|
-$30.35 M
|
-$26.14 M
|
-$21.79 M
|
| Income Before Tax Ratio |
-0.81
|
9.46
|
-1.09
|
-11.94
|
-17.76
|
-14.44
|
-20.04
|
-8.72
|
-7.02
|
-4.02
|
| Income Tax Expense |
$3.00 K
|
$101.00 K
|
$120.00 K
|
$10.00 K
|
$5.00 K
|
$9.00 K
|
$3.00 K
|
$0.00
|
$0.00
|
$90.43 K
|
| Net Income |
-$23.96 M
|
-$68.13 M
|
-$39.70 M
|
-$57.04 M
|
-$47.00 M
|
-$33.59 M
|
-$50.92 M
|
-$30.35 M
|
-$26.14 M
|
-$21.88 M
|
| Net Income Ratio |
-0.81
|
9.48
|
-1.1
|
-11.94
|
-17.76
|
-14.45
|
-20.04
|
-8.72
|
-7.02
|
-4.04
|
| EPS |
-0.5 |
-1.44 |
-1.08 |
-1.64 |
-1.35 |
-1.38 |
-2.35 |
-1.52 |
-1.5 |
-1.43 |
| EPS Diluted |
-0.5 |
-1.44 |
-1.08 |
-1.64 |
-1.35 |
-1.38 |
-2.35 |
-1.52 |
-1.5 |
-1.43 |
| Weighted Average Shares Out |
$47.82 M
|
$47.27 M
|
$36.76 M
|
$34.85 M
|
$34.73 M
|
$24.39 M
|
$21.63 M
|
$19.62 M
|
$17.43 M
|
$15.28 M
|
| Weighted Average Shares Out Diluted |
$47.82 M
|
$47.27 M
|
$36.93 M
|
$34.85 M
|
$34.73 M
|
$24.39 M
|
$21.63 M
|
$19.63 M
|
$17.48 M
|
$15.28 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
